|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.73 CNY | -0.95% |
|
-1.99% | -6.33% |
| 08/05 | Shanghai Pharmaceuticals Gains Thai Approval for Rivaroxaban Tablets | MT |
| 29/04 | Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Capitalization | 5.62TCr 825.49Cr 710.34Cr 649.47Cr 619.67Cr 1.14TCr 79TCr 1.15TCr 7.79TCr 3.02TCr 38TCr 3.1TCr 3.03TCr 1,31000Cr | P/E ratio 2026 * |
10.3x | P/E ratio 2027 * | 10.5x |
|---|---|---|---|---|---|
| Enterprise value | 6.1TCr 896.93Cr 771.81Cr 705.68Cr 673.29Cr 1.23TCr 86TCr 1.25TCr 8.47TCr 3.28TCr 41TCr 3.37TCr 3.29TCr 1,42300Cr | EV / Sales 2026 * |
0.21x | EV / Sales 2027 * | 0.22x |
| Free-Float |
43.02% | Yield 2026 * |
2.93% | Yield 2027 * | 2.84% |
| 1 day | -0.95% | ||
| 1 week | -1.99% | ||
| Current month | -2.11% | ||
| 1 month | -2.39% | ||
| 3 months | -2.51% | ||
| 6 months | -8.68% | ||
| Current year | -6.33% |
| 1 week | 16.67 |  | 17.26 |
| 1 month | 16.67 | | 17.26 |
| Current year | 16.23 | | 18.13 |
| 1 year | 16.23 | | 19.68 |
| 3 years | 15.36 | | 23.98 |
| 5 years | 15.36 | | 28.64 |
| 10 years | 15.36 | | 29.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yong Zhong Li
PSD | President | 56 | 29/06/2023 |
Bo Shen
DFI | Director of Finance/CFO | 53 | 05/06/2013 |
Xue Jun Cai
CTO | Chief Tech/Sci/R&D Officer | 63 | 01/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Bo Shen
BRD | Director/Board Member | 53 | 28/06/2016 |
Yong Zhong Li
BRD | Director/Board Member | 56 | 27/06/2019 |
Manson Fok
BRD | Director/Board Member | 69 | 27/06/2019 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +3.06% | 0% | 33,076 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.95% | -1.99% | -8.58% | -22.33% | 825.49Cr | |
| +1.79% | +3.33% | +5.02% | +92.04% | 9.14TCr | |
| +0.42% | +6.29% | +26.55% | +127.51% | 4.57TCr | |
| 0.00% | +0.35% | -4.35% | +314.49% | 2.35TCr | |
| -4.57% | -5.89% | -22.91% | -25.16% | 806.59Cr | |
| -1.43% | -2.98% | -3.14% | -33.03% | 712.58Cr | |
| -0.43% | -3.90% | +15.72% | +7.65% | 621.29Cr | |
| +0.55% | -0.30% | -4.52% | +9.07% | 521.82Cr | |
| -0.80% | -1.98% | -4.07% | -14.72% | 362.7Cr | |
| +2.78% | +1.33% | +22.71% | +26.44% | 362.44Cr | |
| Average | -0.26% | -0.54% | +2.24% | +48.20% | 2.03TCr | |
| Weighted average by Cap. | +0.67% | +2.40% | +7.07% | +104.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 29TCr 4.29TCr 3.69TCr 3.38TCr 3.22TCr 5.91TCr 4,11800Cr 6TCr 41TCr 16TCr 1,95500Cr 16TCr 16TCr 6,81000Cr | 32TCr 4.63TCr 3.99TCr 3.64TCr 3.48TCr 6.37TCr 4,44300Cr 6.48TCr 44TCr 17TCr 2,10900Cr 17TCr 17TCr 7,34800Cr |
| Net income | 519.21Cr 76Cr 66Cr 60Cr 57Cr 104.99Cr 7.32TCr 106.73Cr 720.17Cr 278.67Cr 3.47TCr 286.32Cr 280.18Cr 12TCr | 593.04Cr 87Cr 75Cr 69Cr 65Cr 119.92Cr 8.36TCr 121.9Cr 822.57Cr 318.3Cr 3.97TCr 327.03Cr 320.02Cr 14TCr |
| Net Debt | 486.15Cr 71Cr 61Cr 56Cr 54Cr 98Cr 6.85TCr 100Cr 674.31Cr 260.93Cr 3.25TCr 268.09Cr 262.34Cr 11TCr | 1.26TCr 185.87Cr 159.94Cr 146.24Cr 139.52Cr 255.78Cr 18TCr 260.01Cr 1.75TCr 678.9Cr 8.47TCr 697.52Cr 682.58Cr 29TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | 16.73 ¥ | -0.95% | 91,27,680 |
| 14/26/14 | 16.89 ¥ | -0.94% | 73,14,653 |
| 13/26/13 | 17.05 ¥ | -0.58% | 86,66,682 |
| 12/26/12 | 17.15 ¥ | 0.00% | 96,87,559 |
| 11/26/11 | 17.15 ¥ | +0.47% | 1,06,97,270 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 601607 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition